Cargando…
Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575309/ https://www.ncbi.nlm.nih.gov/pubmed/36257548 http://dx.doi.org/10.1016/j.cmi.2022.10.016 |
| _version_ | 1784811291232174080 |
|---|---|
| author | Gallagher, Jason C. Morgan, Rebecca L. |
| author_facet | Gallagher, Jason C. Morgan, Rebecca L. |
| author_sort | Gallagher, Jason C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9575309 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95753092022-10-17 Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials Gallagher, Jason C. Morgan, Rebecca L. Clin Microbiol Infect Commentary European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2023-01 2022-10-17 /pmc/articles/PMC9575309/ /pubmed/36257548 http://dx.doi.org/10.1016/j.cmi.2022.10.016 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Commentary Gallagher, Jason C. Morgan, Rebecca L. Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials |
| title | Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials |
| title_full | Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials |
| title_fullStr | Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials |
| title_full_unstemmed | Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials |
| title_short | Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials |
| title_sort | successful immunomodulators for the treatment of covid-19 have opened the pathway for comparative trials |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575309/ https://www.ncbi.nlm.nih.gov/pubmed/36257548 http://dx.doi.org/10.1016/j.cmi.2022.10.016 |
| work_keys_str_mv | AT gallagherjasonc successfulimmunomodulatorsforthetreatmentofcovid19haveopenedthepathwayforcomparativetrials AT morganrebeccal successfulimmunomodulatorsforthetreatmentofcovid19haveopenedthepathwayforcomparativetrials |